| HOME >> BIOLOGY >> TECHNOLOGY |
Non-interest bearing loan from third party - 62,818
Accounts payable 292,504 71,223
Accrued expenses 308,396 523,892
Taxes payable 614,972 218,231
Other payables 11,033 607,595
Other payables - related parties 20,963 16,025
Total current liabilities 1,287,319 1,538,244
OTHER LIABILITIES:
Deferred government grant 986,250 961,500
Liquidated damages 141,267 -
Convertible debenture, net of $3,482,980
discount 397,642 -
Total other liabilities 1,525,159 961,500
Total liabilities 2,812,478 2,499,744
COMMITMENTS AND CONTINGENCIES - -
SHAREHOLDERS' EQUITY:
Preferred stock, $0.001 par value,
50,000,000 shares authorized, 2,000,000
series "A" shares issued and outstanding
as of June 30, 2007 and December 31, 2006,
respectively; Nil series "B" shares issued
and outstanding as of June 30, 2007 and
December 31, 2006, respectively. 2,000 2,000
Common stock, $0.001 par value, 50,000,000
shares authorized; 12,795,549 and 12,795,549
shares issued and outstanding as of June 30,
2007 and December 31, 2006, respectively 12,795 12,795
Paid-in-capital 10,964,602 6,246,325
Deferred compensation (243,603) (705,877)
Statutory reserves 955,555 779,62
'/>"/>
SOURCE Skystar Bio-Pharmaceutical Co.![]() Copyright©2007 PR Newswire. |